Patents
Literature
Patsnap Copilot is an intelligent assistant for R&D personnel, combined with Patent DNA, to facilitate innovative research.
Patsnap Copilot

280 results about "Poloxamer 407" patented technology

Poloxamer 407 is a hydrophilic non-ionic surfactant of the more general class of copolymers known as poloxamers. Poloxamer 407 is a triblock copolymer consisting of a central hydrophobic block of polypropylene glycol flanked by two hydrophilic blocks of polyethylene glycol (PEG). The approximate lengths of the two PEG blocks is 101 repeat units while the approximate length of the propylene glycol block is 56 repeat units. This particular compound is also known by the BASF trade name Pluronic F127 or by the Croda trade name Synperonic PE/F 127.

Amphipathic polysaccharide derivative/poloxamer thermo-sensitive type in-situ hydrogel and preparation method thereof

InactiveCN104888224ATo achieve the purpose of slow-release drugsGelation time is shortPharmaceutical non-active ingredientsPerylene derivativesBioavailability
The invention discloses amphipathic polysaccharide derivative/poloxamer thermo-sensitive type in-situ hydrogel and a preparation method thereof. The thermo-sensitive type in-situ hydrogel is prepared in the mode that amphipathic polysaccharide series derivatives, poloxamer polymer and hydrophobic drugs interact to form stable in-situ hydrogel, the gelatinization temperature of the thermo-sensitive type in-situ hydrogel ranges from 34 DEG C to 37 DEG C, and the gelatinization time for forming the in-situ hydrogel at the gelatinization temperature ranges from one to three minutes. The poloxamer polymer is the mixture of poloxamer 407 and any one kind of poloxamer of other types. Compared with common amphipathic/poloxamer in-situ hydrogel, the in-situ hydrogel is higher in stability and longer in drug sustained release time, parenteral drug delivery and improving of drug bioavailability are made possible, and the in-situ hydrogel can be applied to mucous membrane drug delivery, transdermal drug delivery and parenteral drug delivery systems; the preparation method of the mphipathic polysaccharide derivative/poloxamer thermo-sensitive type in-situ hydrogel is convenient to operate, simple in process and cheap in needed equipment and raw material.
Owner:SUN YAT SEN UNIV

Preparation method of ceftiofur acid long-acting injection

The invention belongs to the technical field of preparation of medicines and in particular relates to a preparation method of ceftiofur acid long-acting injection. The preparation method comprises the followings steps of: adding ceftiofur acid and 2-hydroxypropyl-beta-cyclodextrin in a molar ratio of 1:(1-2) to a ball mill for uniformly mixing; sufficiently grinding under the room temperature, and sufficiently uniformly and sieving to obtain a ceftiofur acid clathrate compound; dissolving sodium alginate in sterile water and adding poloxamer 407 and poloxamer 188, storing for 12-24 hours under the temperature condition of 4 DEG C, so that the poloxamer 407 and the poloxamer 188 are completely dissolved and sterilized under the temperature of 121 DEG C, carrying out ice-bath cooling to obtain a transparent solution; magnetically stirring under the temperature condition of 4 DEG C and the rotation speed condition of 150r/min; adding the ceftiofur acid clathrate compound in a weight ratio of the sodium alginate to the ceftiofur acid clathrate compound of (0.1-0.3):(5-10), so that the ceftiofur acid clathrate compound is sufficiently dispersed uniformly to obtain the ceftiofur acid long-acting injection. According to the preparation method of the ceftiofur acid long-acting injection, the preparation process is simple, the product intramuscular injection half-life period is long, the dissolution degree of the ceftiofur acid is high, the production and treatment cost is low, the cure rate is high and the environment is friendly.
Owner:QINGDAO AGRI UNIV

Compound temperature-sensitive gel for treating skin ulcer and preparation method thereof

The invention relates to a compound temperature-sensitive gel for treating skin ulcer and a preparation method thereof. The compound temperature-sensitive gel is composed of insulin and recombinant human epidermal factor by taking one or more of poloxamer 407, poloxamer 188 and chitosan as a substrate; and the compound temperature-sensitive gel is prepared through preparation of a gel substrate, preparation of a mixed solution of the insulin and the recombinant human epidermal factor, preparation of the compound temperature-sensitive gel and observation of a sample in turn. The compound temperature-sensitive gel disclosed by the invention is in the liquid state in preparation and storage processes and easy to coat or spray at a wound, so that the compound temperature-sensitive gel is conveniently used clinically; gel can be rapidly formed under the body temperature condition; the gel is difficult to run away, effective for long-term retention and high in bioavailability; furthermore, due to the aqueous environment of the gel, biological activity of two protein medicaments can be ensured more easily; release of the two protein medicaments is more easy; and the preparation method of the compound temperature-sensitive gel disclosed by the invention is simple and practical and strong in operability.
Owner:卓阳

Nasal administration gel preparation for treating brain diseases

The invention discloses a nasal drug delivery gel preparation for curing cerebral diseases. Water is used as solvent in the preparation. The preparation includes geniposide or total iridoid glycoside of cape jasmine fruit, poloxamer 407 and poloxamer 188. The phase transformation temperature of the preparation is 25-35 DEG C. Based on the weight of the preparation, the geniposide or total iridoid glycoside of cape jasmine fruit is 1-5%; the poloxamer 407 is 16-18%; the poloxamer 188 is 0-5%; preferably, based on the weight of the preparation, the preparation is composed of 2% of the geniposide, 16% of the poloxamer 407, 2.5% of the poloxamer 188, 0.2% of ethylparaben, 0.9% of sodium chloride and the balance of water; and the phase transformation temperature of the preparation is 25-33 DEG C. According to the preparation disclosed by the invention, the gel preparation has proper phase transformation temperature by adjusting kinds and proportions of gelling matrixes in the preparation; after the gel preparation is sprayed in a nasal cavity in the form of solution so that gel is rapidly formed under a body temperature condition, therefore, the contact time of the geniposide or total iridoid glycoside of cape jasmine fruit and nasal mucosa is increased; and the distribution of drugs in brain tissue is increased.
Owner:JIANGXI UNIVERSITY OF TRADITIONAL CHINESE MEDICINE

Temperature-sensitive gel for skin injury and preparation method of temperature-sensitive gel

The invention discloses a temperature-sensitive gel for a skin injury and a preparation method of the temperature-sensitive gel and relates to the technical field of skin repair administration. The temperature-sensitive gel is prepared from the following raw materials in parts by weight: 5-20 parts of poloxamer 407, 0.01-0.1 part of a bacteriostatic agent, 0.001-0.05 part of a human epidermal growth factor, 0.2-1.0 part of a humectant, 2-10 parts of sodium hyaluronate and the balance of water for injection water. The temperature-sensitive gel is prepared from the poloxamer 407 as a main raw material, and exists in a solution form at a low temperature; administration is convenient; the temperature-sensitive gel is converted into a gel state at a high temperature and is smooth and soft in surface, free of thrill to the administration part, free of foreign body sensation and good in biocompatibility; the sodium hyaluronate is very high in biocompatibility, beneficial to long-term moisture retention of the skin and beneficial to tissue cell regeneration and is capable of compacting the skin and preventing dehydration; and the human epidermal growth factor has an acceleration effect on mucosa repairing of the skin injury, so that the wound healing cycle is shortened to meet the structure design and clinical requirements.
Owner:XIAN HUIPU BIOTECH CO LTD
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products